Omnicell (OMCL) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and Omnicell published the results on October 29, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison. Omnicell reports EPS two ways: GAAP, under the accounting rules every US filer follows, and non-GAAP, which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

Source: Omnicell Q3 2026 results, October 29, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Omnicell splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Omnicell's Product revenues revenue was $173 million in Q3 2026, down 3% from $177 million in Q3 2025, 56% of total revenue.
• Omnicell's Service revenues revenue was $135 million in Q3 2026, up 1% from $133 million in Q3 2025, 44% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

Omnicell gives its outlook as a table in the release. For Q4 2026: total revenues of $295 million to $301 million, non-GAAP EBITDA of $30 million to $36 million and non-GAAP EPS of $0.41 to $0.49. For full year 2026: product bookings of $425 million to $560 million, annual recurring revenue of $660 million to $670 million, total revenues of $1.225 billion to $1.231 billion, non-GAAP EBITDA of $187 million to $193 million and non-GAAP EPS of $2.48 to $2.56. Omnicell does not guide GAAP net income or GAAP EPS.

In its Q3 2026 release, Omnicell said:

“Given our strong third quarter 2026 profitability performance and continued focus on disciplined execution, we are increasing our full year 2026 non-GAAP EBITDA and non-GAAP earnings per share guidance ranges.”

“We are reiterating our product bookings guidance range, which continues to reflect our current assessment of the range of potential outcomes for full year 2026.”

Source: Omnicell Q3 2026 release, Oct 29, 2026.

This is the company's own guidance as of Oct 29, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the OMCL forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP revenue and diluted EPS, each as first reported in that quarter's release.

We do not hold a confirmed date for Omnicell's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Oct 29, 2026

Omnicell sells medication management automation to hospitals and pharmacies, and reports product and service revenue. In Q3 2026 product revenues were $173.1 million, of which connected devices, software licenses and other made up $146.1 million and consumables $26.9 million. Service revenues were $134.8 million, split between technical services ($67.8 million) and SaaS and Expert Services ($67.0 million). (Omnicell Q3 2026 release, Oct 29, 2026; Omnicell Form 10-Q, Q3 2026, Nov 4, 2026)

Total revenue fell 1% to $307.9 million. Omnicell said product revenues decreased by $4.4 million because of lower volumes from its XTExtend offering, partly offset by higher revenue from XT Series automated dispensing systems. Service revenues rose $1.7 million, including $1.2 million more from SaaS and Expert Services on growth in Specialty Pharmacy Services, partly offset by lower EnlivenHealth and 340B revenue. (Omnicell Q3 2026 release, Oct 29, 2026; Omnicell Form 10-Q, Q3 2026, Nov 4, 2026)

The United States accounted for $271.8 million of Q3 2026 revenue and the rest of the world $36.0 million; international sales were 12% of revenue, up from 10%. Omnicell sells largely through group purchasing organizations: in 2025, members of the ten largest GPOs and federal agencies buying under its GSA contract accounted for about 61% of revenue. (Omnicell Form 10-Q, Q3 2026, Nov 4, 2026; Omnicell Form 10-K, 2025, Feb 26, 2026)

Service revenue is recurring and contracted. Remaining performance obligations not yet in deferred revenue were $375.1 million at September 30, 2026, covering the non-variable portions of technical services and SaaS and Expert Services contracts, which generally run up to ten years. (Omnicell Form 10-Q, Q3 2026, Nov 4, 2026)

Omnicell's GAAP diluted EPS doubled to $0.24 in Q3 2026 from $0.12 a year earlier. Gross profit rose to $137.8 million from $134.5 million on lower cost of service revenues, and operating expenses fell to $122.9 million from $126.3 million. The year-ago quarter carried a $2.6 million EnlivenHealth restructuring charge. (Omnicell Q3 2026 release, Oct 29, 2026)

Non-GAAP EPS was $0.58, against $0.51. Omnicell's per-share reconciliation adds back $0.25 of share-based compensation, $0.10 of amortization of acquired intangibles, $0.01 of China restructuring and $0.01 of debt issuance cost amortization, less $0.03 of tax effect, calculated at an estimated annual effective tax rate of 21%. (Omnicell Q3 2026 release, Oct 29, 2026)

Diluted weighted-average shares were 46,466 thousand in Q3 2026, against 45,900 thousand a year earlier. The provision for income taxes was $4.8 million on pre-tax income of $15.8 million. (Omnicell Q3 2026 release, Oct 29, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Omnicell gives quarterly and full-year guidance in a table in its release, on a non-GAAP basis, and does not guide GAAP EPS. With Q3 2026 results it raised its full-year non-GAAP EBITDA range to $187 million to $193 million and non-GAAP EPS to $2.48 to $2.56, tightened full-year revenue to $1.225 billion to $1.231 billion, and kept product bookings guidance at $425 million to $560 million. For Q4 2026 it guided revenue of $295 million to $301 million and non-GAAP EPS of $0.41 to $0.49. (Omnicell Q3 2026 release, Oct 29, 2026)

A consensus figure is the average of the models published by the analysts who cover Omnicell, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Omnicell's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning OMCL is on is OMCL a buy or a sell?, what analysts expect next is on the OMCL forecast, and what the company does is on the Omnicell (OMCL) stock page.

Every number on this page can be traced to a document Omnicell published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.